Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Fiche publication
Date publication
décembre 2017
Journal
Expert review of pharmacoeconomics & outcomes research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-Biroulet L, Lakatos PL, Brodszky V
Lien Pubmed
Résumé
This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries.
Mots clés
Adalimumab, Crohn’s disease, biosimilar infliximab, cost-effectiveness, inflammatory bowel diseases, infliximab, vedolizumab
Référence
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):597-606